Helicobacter pylori Eradication for Aspirin-Associated Peptic Ulcer Bleeding Prevention
The provided citation reports evaluation of H. pylori eradication in chronic aspirin users for prevention of peptic ulcer bleeding and for cardiovascular disease (CVD) progression outcomes. A closely related evidence base comes from the HEAT randomized trial in older aspirin users, which showed H. pylori eradication reduced aspirin-associated ulcer bleeding early, with attenuation over longer follow-up. [1] [2]
Scope of the Referenced World Journal of Gastroenterology Article
The World Journal of Gastroenterology article cited (Semeya et al., 2026; DOI: 10.3748/wjg.v32.i17.117544) could not be fully retrieved from authoritative indexing in the available lookup results, so the specific design, population size, effect estimates, and CVD progression outcomes from that exact paper could not be verified here. (eurekamag.com)
Core Evidence Supporting Aspirin-Ulcer Bleeding Risk Reduction
In the HEAT randomized, double-blind, placebo-controlled trial, participants were ≥60 years old with chronic aspirin exposure (≤325 mg daily) and positive H. pylori testing. [2]
During follow-up in HEAT, eradication treatment was associated with a 65% reduction in the primary ulcer-bleeding outcome in an early time period (median follow-up window), with no statistically clear difference when longer follow-up data were included. [3]
Clinical Implications for Chronic Aspirin Users (Test-and-Treat Concept)
A test-and-treat strategy for H. pylori in chronic aspirin users is biologically and empirically supported by the observed reduction in aspirin-associated ulcer bleeding with eradication in HEAT. [2]
Evidence Gaps for Cardiovascular Disease Progression Outcomes
No cardiovascular progression effect size from Semeya et al. (2026) could be verified from the available lookup results. (eurekamag.com)
Citation Requested for Correct Use
To generate a guideline-style evidence synthesis of the Semeya et al. (2026) paper’s exact findings (including CVD progression results), the full abstract or full text content is needed (or permission to perform a targeted lookup until the PubMed or publisher record is retrieved). (eurekamag.com)
What deliverable is needed—(1) a structured abstract-style summary, (2) extraction of effect estimates for ulcer bleeding and CVD progression, or (3) a clinical recommendation statement?